All FDA approved drugs for treatment of patients with high blood pressure (renin inhibitors, ACEi, and ARBs) are primarily designed to block or reduce the detrimental effects of Ang II (Wright, 2000; Mentz et al., 2013; Arendse et al., 2019; Figure 10A). Here, REN is linked to hypertensive disorder.